其 他 安 全 警 示
|
| |
| The United Kingdom: Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (English only) |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that falsified, potentially harmful Ozempic and Saxenda products have been found in the UK.
Up to October 2023 the MHRA has seized 369 potentially falsified Ozempic pens. None were seized before January 2023. The MHRA have also received reports of falsified Saxenda pens that have been obtained by members of the public in the UK through non-legitimate routes (any route that does not require a prescription from a qualified prescribing healthcare professional).
Advice for healthcare professionals:
• be aware that falsified Ozempic and Saxenda products have been found in the UK, including falsified pens containing insulin, which may lead to patient harm
• remain vigilant for symptoms linked to hypoglycaemia in patients who may have obtained a falsified product and provide appropriate treatment for any patient who may have inadvertently administered insulin via these products
• if you encounter a suspected falsified product, quarantine it and report it
• advise patients who are concerned that the pens they have purchased might be falsified that they should not use the pens and report
• Ozempic and Saxenda from legitimate supply chains are unaffected
Please refer to the following website in MHRA for details:
https://www.gov.uk/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products
In Hong Kong, Ozempic Solution For Injection In 1.5ml Pre-filled Pen 0.25mg/dose (HK-66485), Ozempic Solution For Injection In 1.5ml Pre-filled Pen 0.5mg/dose (HK-66486), Ozempic Solution For Injection In 3.0ml Pre-filled Pen 1mg/dose (HK-66487) and Saxenda Solution For Injection In Pre-Filled Pen 18mg/3ml (HK-67971 and HK-65010) are pharmaceutical products registered by Novo Nordisk Hong Kong Ltd. The products are prescription-only medicine. The Department of Health will remain vigilant on safety update against the captioned issue.
Ends/Saturday, Nov 25, 2023
Issued at HKT 12:00
|
| |
